And the fun for the company does not stop with ABRAXANE or the oncology market. Earlier in this article, we mentioned investigational applications of the nab technology in the huge ($$$) stent market. COROXANE is nab paclitaxel. The anti-proliferative effect of sirolimus (rapamycin) has also been used in the production of sirolimus-eluting stents used to treat obstructed coronary arteries, as it is believed that sirolimus-eluting stents (marketed by Cordis as the Cypher stent) are less likely to cause restonosis, too. The anti-thrombin inhibitor rapamycin is currently under review by Abraxis—as nab rapamycin.
2006/7/21
訂閱:
張貼留言 (Atom)
沒有留言:
張貼留言